Crucell Receives Grant for Flu Vaccine
Posted on: Thursday, 5 April 2007, 12:00 CDT
Dutch biotechnology company Crucell has received a European Commission-funded grant toward the development of a pandemic influenza vaccine.
The E1.7 million grant which was awarded to a consortium of nine leading universities and companies working in the field of influenza research, will finance preclinical and clinical testing of H5N1 vaccines.
"With a vaccine already in clinical trial based on H9N2, Crucell broadens its pandemic influenza vaccine portfolio adding another potential pandemic strain," said Dr Jaap Goudsmit, Crucell's chief scientific officer.
Three influenza subtypes, H5, H7 and H9 have caused highly pathogenic avian influenza. Although presently most vaccine development has focused on H5N1 strains, avian H7 and H9 influenza subtypes remain a pandemic threat and have caused infection in humans in Asia and Europe since 1996.
Source: Datamonitor
Related Articles
- Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
- Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
- European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
- Crucell Secures Important Patent Covering Influenza Vaccine Production
- GlaxoSmithKline Files Its New Pre-Pandemic Influenza Vaccine in Europe
- Sinovac Announces Pandemic Influenza Vaccine Phase I Clinical Trial Preliminary Results
- Adjuvanted Formulation of Sanofi Pasteur H5N1 Pandemic Influenza Vaccine Candidate Demonstrates Significant Immune Response
- Novavax and Bharat Biotech Announce Strategic Alliance for Pandemic Influenza Vaccine Development
- Sanofi Pasteur Announces Preliminary Trial Results for a First H5N1 Pre-Pandemic Influenza Vaccine Candidate With an Adjuvant
- Crucell Updates Progress in Scale-Up of Cell-Culture-Based Influenza Vaccine Programs
 |
 |
User Comments (0)
RSS Feeds